Pharmaceutical Technology Europe
It's all well and good providing drugs for people who need them, but it becomes a lot more difficult if they choose to ignore the warnings
Just after Christmas, I read a report in a newspaper describing how it is easier to contract HIV in the villages surrounding Zambia's Lake Mweru than it is to catch fish in the water — and that's not through a lack of aquatic life. An awful statistic, but one that didn't really surprise me — after all, most of us are fully aware of the HIV problems in Africa.
Gurminder Marwaha
What is alarming, however, is that while much is made of drug companies and their seeming reluctance to provide free/cheap/generic products to help stem the rise in the number of people affected, they, and organizations such as Médecins Sans Frontières (MSF), face an uphill struggle to get to what is arguably the heart of the matter — education. It's all well and good providing drugs for people who need them, but it becomes a lot more difficult if that group of people continually gets bigger and bigger. Whose fault is it if people choose to ignore the warnings about the effects of HIV, or are ignorant of the problem in the first place? Drug manufacturers cannot be blamed for the failure of humans to understand or believe the risks involved in their behaviour.
While we applaud the work of MSF and the World Health Organization, and no doubt the stance of drug companies is slowly changing, we have to look at how the wider issues could be addressed. It's all very well blaming drug companies; after all, they are an easy target because they have the potential solutions. But it needs drugs combined with properly implemented educational initiatives to fully raise awareness in the world's poorest continent.
And that's an area where drug manufacturers could help — assisting governments of the poorest countries to set up community programmes. In a way, you almost feel that its the governments themselves that need educating. Not only would this help their populations to better understand the wider issues, it would also go some way in demonstrating that drug manufacturers are taking HIV in poor countries seriously and that they are able to look beyond the profits. It's not just about fancy websites — no good for a population that can barely feed itself. It's about providing the right infrastructure for people to prevent and/or deal with HIV. But, it's not something the pharmaceutical industry can do by itself, and hence the blame cannot lie solely at its feet.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.